Epidermology of tb and investigation psm k park detail easy language
| Fact | Detail |
|---|---|
| Population infected (silent) | ~1/3rd of world population asymptomatically infected |
| Who develops disease | 5-10% of infected develop clinical TB in their lifetime |
| New cases/year (2019) | ~10 million globally |
| Annual infection risk in high burden countries | 0.5-2% |
| One patient spreads to | 10-15 persons per year |
| TB deaths (HIV-negative, 2019) | 1.2 million |
| TB deaths (HIV-positive, 2019) | 208,000 |
| Gender split | Men 56%, Women 32%, Children <15 yrs 12% |
90% of TB's economic burden = loss of life, not just illness.
| Index | Meaning |
|---|---|
| Incidence | New + recurrent (relapse) TB episodes in a given year |
| Prevalence | Total TB cases (all forms) at a given point in time; best index for case load |
| Mortality | Deaths due to TB (HIV-negative counted separately from HIV-positive per ICD-10) |
| Case Fatality Rate | Risk of death among those with active TB |
| Case Notification Rate | New + recurrent TB cases notified to WHO per 100,000 population per year |
| Case Detection Rate | Notifications of new+relapse cases ÷ Estimated incidence × 100 |
| Type | Definition |
|---|---|
| Mono-resistance | Resistant to ONE first-line drug only |
| Polydrug resistance | Resistant to >1 first-line drug (but NOT both INH + Rifampicin together) |
| MDR-TB | Resistant to at least BOTH Isoniazid (INH) and Rifampicin |
| XDR-TB | MDR + resistant to any fluoroquinolone + at least one second-line injectable (kanamycin, amikacin, capreomycin) |
| Rifampicin Resistance (RR-TB) | Resistance to Rifampicin by any method (includes MDR + XDR) |
| Method | Detail |
|---|---|
| Solid culture (LJ medium) | Gold standard but takes 6-8 weeks |
| Liquid culture (MGIT-960, BacT Alert, Versatrek) | Faster; results in up to 42 days |
| Drug Sensitivity Testing (DST) | Available 14-26 days after culture turns positive |
| Test | What it detects |
|---|---|
| CBNAAT / TrueNat (NAAT) | MTB + Rifampicin resistance (rpoB gene) |
| Line Probe Assay (LPA) - FL LPA | MTB complex + RIF & INH resistance |
| Line Probe Assay - SL LPA | Fluoroquinolone + Second-line injectable resistance |
| PCR-based methods | rpoB (Rifampicin), katG + inhA (Isoniazid) resistance genes |
| Test | Use | Key Point |
|---|---|---|
| Sputum Smear (ZN stain) | Primary case finding | Cheap, fast, most used |
| Culture (LJ/MGIT) | Confirmation + DST | Takes weeks |
| CBNAAT/TrueNat | Rapid diagnosis + Rif resistance | Done in 2 hours |
| LPA (FL/SL) | First/second-line drug resistance | For MDR/XDR-TB |
| Mantoux/TST | Infection screen | Does NOT confirm active TB |
| IGRA | Infection screen | More specific than TST |
| Chest X-ray | Supportive | Not confirmatory |